{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:15:11Z","timestamp":1790378111089,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005936","name":"Casio Science Promotion Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007434","name":"Suzuken Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16H06909"],"award-info":[{"award-number":["16H06909"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["26670754"],"award-info":[{"award-number":["26670754"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jconrel.2017.09.036","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T14:30:41Z","timestamp":1507732241000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases"],"prefix":"10.1016","volume":"266","author":[{"given":"Kenji","family":"Suda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-500X","authenticated-orcid":false,"given":"Tatsuya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimoto","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagahisa","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.09.036_bb0005","unstructured":"Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. World Health Organization, New York City, NY, 16 September 2011. Available from URL: http:\/\/www.who.int\/nmh\/events\/un_ncd_summit2011\/political_declaration_en.pdf."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2183\/pjab.89.462","article-title":"Life course health care and preemptive approach to non-communicable diseases","volume":"89","author":"Imura","year":"2013","journal-title":"Proc. Jpn Acad. Ser. B"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s11095-006-0284-8","article-title":"Nanotechnology: intelligent design to treat complex disease","volume":"23","author":"Couvreur","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990\u20132010: a systematic analysis","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0030","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0035","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","article-title":"Ocular complications after antivascular endothelial growth factor therapy in medicare patients with age-related macular degeneration","volume":"152","author":"Day","year":"2011","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2011.05.016","article-title":"Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats","volume":"666","author":"Yafai","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ophtha.2014.09.036","article-title":"Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration","volume":"122","author":"Csaky","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0060","first-page":"172","article-title":"Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration","author":"Danis","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ng.2578","article-title":"Seven new loci associated with age-related macular degeneration","volume":"45","author":"Fritsche","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0070","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.preteyeres.2014.03.002","article-title":"Cholesterol in the retina: the best is yet to come","volume":"41","author":"Pikuleva","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1194\/jlr.R002238","article-title":"Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration","volume":"51","author":"Curcio","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0085","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease","volume":"62","author":"Gordon","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(75)92376-4","article-title":"Plasma-high-density-lipoprotein concentration and development of isch\u00e6mic heart-disease","volume":"305","author":"Miller","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0095","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0026-895X(25)13216-1","article-title":"Development of lipoprotein-like lipid particles for drug targeting: neo-high density lipoproteins","volume":"44","author":"Schouten","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/nn103098m","article-title":"Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures","volume":"5","author":"Bricarello","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0110","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2217\/nnm.10.66","article-title":"Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles","volume":"5","author":"Murakami","year":"2010","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0115","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1167\/iovs.09-4697","article-title":"Physicochemical properties affecting retinal drug\/coumarin-6 delivery from nanocarrier systems via eyedrop administration","volume":"51","author":"Inokuchi","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0076-6879(86)28092-1","article-title":"Reconstitution of high-density lipoproteins","volume":"128","author":"Jonas","year":"1986","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0125","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0076-6879(86)28067-2","article-title":"Density gradient ultracentrifugation of serum lipoproteins in a swinging bucket rotor","volume":"128","author":"Kelley","year":"1986","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2009.02.020","article-title":"Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye","volume":"136","author":"Hironaka","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/FTD.0000000000000121","article-title":"Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice","volume":"37","author":"Escudero-Ortiz","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0140","doi-asserted-by":"crossref","first-page":"12176","DOI":"10.1073\/pnas.0803626105","article-title":"Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes","volume":"105","author":"Silva","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0145","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1167\/iovs.14-14087","article-title":"Therapeutic potential of semaphorin 3E for the treatment of choroidal neovascularization","volume":"55","author":"Suda","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0150","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1167\/iovs.07-1194","article-title":"Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes","volume":"49","author":"Campa","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0155","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1161\/01.ATV.0000165694.39518.95","article-title":"Apolipoprotein A-I mimetic peptides - ATVB in focus","volume":"25","author":"Navab","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0160","doi-asserted-by":"crossref","first-page":"10801","DOI":"10.1021\/acsnano.5b03124","article-title":"GM1-modified lipoprotein-like nanoparticle: multifunctional nanoplatform for the combination therapy of Alzheimer's disease","volume":"9","author":"Huang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0165","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0170","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.nano.2015.04.015","article-title":"Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases","volume":"11","author":"Jo","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0175","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.biomaterials.2007.12.037","article-title":"Particle size-dependent organ distribution of gold nanoparticles after intravenous administration","volume":"29","author":"De Jong","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbalip.2008.03.003","article-title":"Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I","volume":"1781","author":"Massey","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0185","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0190","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/bjo.2008.144006","article-title":"Expression of reverse cholesterol transport proteins ATP-binding cassette A1 (ABCA1) and scavenger receptor BI (SR-BI) in the retina and retinal pigment epithelium","volume":"93","author":"Duncan","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0195","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/mp400681n","article-title":"Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery","volume":"11","author":"Liu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2017.09.036_bb0200","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.colsurfb.2011.06.025","article-title":"Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye","volume":"88","author":"Araujo","year":"2011","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0205","series-title":"Cell-penetrating Peptides - Methods and Protocols","author":"Lindgren","year":"2015"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.01.010","article-title":"Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms","volume":"201","author":"De Jesus","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1039\/C5TB01332A","article-title":"High-density lipoproteins for therapeutic delivery systems","volume":"4","author":"Kannan Mutharasan","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0220","series-title":"High Density Lipoproteins: From Biological Understanding to Clinical Exploitation","author":"von Eckardstein","year":"2015"},{"key":"10.1016\/j.jconrel.2017.09.036_bb0225","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jacl.2013.08.001","article-title":"High-density lipoproteins: a consensus statement from the National Lipid Association","volume":"7","author":"Toth","year":"2013","journal-title":"J. Clin. Lipidol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917308702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917308702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:50:13Z","timestamp":1750927813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917308702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":45,"alternative-id":["S0168365917308702"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}